HealthTree
[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Double-Blind Randomized Placebo Controlled Trial of Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain


Description

Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the effect of instilling bupivacaine in the bladder following ureteroscopy. This is a randomized study that will investigate the effect of instilling bupivacaine in the bladder following routine ureteroscopy, laser lithotripsy and ureteral stenting in the treatment of stone disease. Compared to a placebo of Normal Saline, our study hypothesizes that administration of topical bupivacaine in the bladder will decrease post-operative pain and lower urinary tract symptoms while improving quality of life in the early post-operative period.

Trial Eligibility

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study. * Male or female, aged ≥ 18 years old. * Diagnosis of nephrolithiasis planned for flexible or semi-rigid ureteroscopy in the treatment of stone disease with ureteral stenting. Exclusion Criteria: * Foley catheterization * History of allergy to bupivacaine * Antegrade ureteroscopy * Transplant or ectopic kidney * Ureteral or bladder reconstruction * Pregnancy (which is a contraindication to elective ureteroscopy) * Dialysis * Surgical complication (significant bleeding, ureteral perforation, significant urothelial damage) * Suspicion of untreated urinary tract infection * History of pelvic radiation * Neurologic disease with a diagnosis of neurogenic bladder dysfunction * History of chronic pain (fibromyalgia, interstitial cystitis, opioid abuse)

Study Info

Organization

University of Chicago


Primary Outcome

Post-operative pain as determined by the score on a Visual Analog Scale (VAS) upon emergence from anesthesia


Outcome Timeframe At 30 minutes post-emergence, 60 minutes post-emergence, 6 hours post-emergence and on post-operative day 1

NCTID NCT06635889

Phases PHASE2

Primary Purpose TREATMENT

Start Date 2024-12-13

Completion Date 2029-10

Enrollment Target 116

Interventions

DRUG Bupivacaine

OTHER Normal saline

Locations Recruiting

The University of Chicago Medical Center

United States, Illinois, Chicago


Interested in joining this trial?

Our dedicated patient navigators are here to support you by reviewing the eligibility criteria to see if you might qualify for this trial.

newsletter icon

Sign Up for Exclusive Kidney Disease Updates & Resources.

By subscribing to the Healthtree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.